Business
How latest rise in oil prices will affect cost of petrol and inflation
As the Iran war continues to escalate, all eyes are on the price of oil as fears mount over a global energy crisis.
Brent prices have spiked as high as about $120 per barrel and are currently around 40 per cent higher than when Israel and the United States attacked Iran on 28 February, starting the war.
In retaliation, Iran kept its stranglehold on shipping through the Strait of Hormuz, the strategic waterway through which a fifth of the world’s oil transits on its way from the Persian Gulf to the open seas, crippling oil prices.
So how does this affect you? Oil prices, benchmarked globally by Brent crude from the North Sea, fluctuate based on supply and demand.
The longer that the price of oil is high, the more difficult it is to absorb those spikes, making it more likely people will feel the cost at home.
Beyond higher heating bills, rising oil costs increase manufacturing and transport expenses, inflating the prices of food and most other goods and services.
“You never know exactly the timeframe of this, but, in the worst case, this is a weeks, not a months thing,” US energy secretary Chris Wright said earlier this week. But the longer it goes on, the more likely it is that prices remain higher afterwards.
Here is what will be affected by the ongoing conflict:
Petrol
Iran has cut its oil output drastically, now only producing a quarter of what it was before the first US strikes fell.
“This is roughly 3 per cent of global oil supply lost in a single event. Shockingly, this is worse than the oil supply situation after Russia attacked Ukraine,” noted XTB research director Kathleen Brooks.
Petrol prices in the UK have been rising since the conflict in the Middle East started, up between 4p and 8p to hit their highest in nearly 20 months.
The RAC said diesel prices had risen by nearly 9 per cent since 28 February. Petrol prices were on average 6 per cent more across the same period.
The government has said drivers can compare prices at different petrol stations across the UK through its fuel finder scheme, which has also been welcomed by the AA.
The cost of heating oil has already doubled, which affects customers using home heating oil, as it is not covered by Ofgem’s energy price cap.
Inflation and interest rates
While we don’t know the figures just yet, we do know that if costs of energy, raw materials and labour go up, prices go up in response- this is inflation.
If prices start to surge again, one of the key measures the Bank of England has to control inflation is to raise interest rates.
“Markets are already pricing in the unwelcome return of uncomfortable levels of inflation, with bond yields rising significantly and investors eyeing the UK as particularly sensitive to an energy shock,” Danni Hewson, head of financial analysis at AJ Bell, said.
“Preventing inflation from spiralling once again will be at the forefront of rate setters’ minds when they sit down to rewrite the Bank’s playbook next week.
“The key consideration will be the duration of the conflict, and whether it ends decisively or if attacks on shipping and energy infrastructure continue beyond any declaration of victory by the US president.”
Mortgages
The interest rate going up means you pay more on the amount you’ve borrowed, if you don’t have a fixed deal.
Some lenders have now raised their rates on new fixed-term mortgages. NatWest, TSB, HSBC, Nationwide, Santander, the Co-operative Bank and Skipton Building Society are among those to have done so in the past week or so.
Typically, mortgage deals on the market don’t change in direct line with the Bank of England base rate, they move up and down in anticipation of what might happen in future – with the swap rates, as they are termed.
Up until recently, mortgage prices had been headed downwards, but with this new threat to a possible rise in interest rates, swap rates have edged up.
Stock market and pensions
If inflation and interest rates are potentially heading up, the opposite is currently true for the stock market.
The FTSE 100 fell more than 5 per cent across last week after the chaos in the Middle East began.
Business
‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’
Sarah has now got her money back but there are calls to reform the deadline for reporting scams to banks.
Source link
Business
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.
Spencer Grant | Universal Images Group | Getty Images
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.
The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.
Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.
The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.
“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.
The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.
Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.
If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.
Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.
Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.
“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”
Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.
Business
European flight prices are falling in short-term, Wizz Air boss says
While many airlines say they are raising prices due to high fuel costs, József Váradi says European airlines are trying to boost demand
Source link
-
Sports1 week agoNCAA men’s gymnastics championship: All-time winners list
-
Sports1 week agoWWE WrestleMania 42 Night 2: Live match results and analysis
-
Politics7 days agoUK’s Starmer seeks to deflect blame over Mandelson appointment
-
Fashion1 week agoUK’s Sosandar returns to profitability amid robust FY26 performance
-
Entertainment1 week agoLee Anderson, Zarah Sultana kicked out of UK Parliament for calling PM ‘liar’
-
Business1 week agoHow Trump’s psychedelics executive order could unlock stalled cannabis reform
-
Business1 week agoNo fuel shortage: Govt assures 100% domestic LPG, PNG, CNG supply amid Hormuz energy crunch – The Times of India
-
Sports1 week agoQuetta Gladiators opt to bowl after winning toss against Peshawar Zalmi in PSL 11 clash
